Search results for "CD40 LIGAND"

showing 10 items of 30 documents

CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke.

2009

Aim: Up-regulation of soluble CD40 ligand (sCD40L) and of monocyte chemoattractant protein-1 (MCP-1) has been found in diabetes and in patients with acute cerebral ischemia. We asked whether (i) the two molecules are similarly upregulated among non-lacunar and lacunar diabetic strokes and (ii) sCD40L and/or MCP-1 predict the risk of cardiovascular events in this setting.Methods: Ninety patients with type 2 diabetes mellitus presenting with an acute ischemic stroke (compared with 45 control subjects) were evaluated on admission and up to 36 months (median 24 months) after the event.Results: Diabetic patients with acute stroke had higher plasma CD40L and MCP-1 than controls (p<0.0001), wit…

MaleRiskCD40 ligand stroke diabetesmedicine.medical_specialtystrokeCD40L MCP-1Settore MED/09 - Medicina Internacerebral ischemia; chemokines; cytokines; diabetes mellitusCD40 LigandIschemiachemokinesDiseasecerebral ischemiaCohort StudiesDiabetes ComplicationsInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusMedicineCD40LHumanscardiovascular diseasesStrokeChemokine CCL2Ageddiabetesbusiness.industryProportional hazards modelBiochemistry (medical)Type 2 Diabetes MellitusMiddle Agedmedicine.diseasecytokinesSurgeryStrokeTreatment OutcomeQuartileGene Expression RegulationCardiologyRegression AnalysisFemaleCardiology and Cardiovascular MedicinebusinessCohort studyMCP-1
researchProduct

Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis

2005

Background and Purpose— We investigated whether soluble CD40L (sCD40L) may predict the risk of cardiovascular (CV) events in patients with asymptomatic carotid plaques. Methods— Forty-two patients with asymptomatic low-grade carotid stenosis (ALCS) and 21 controls without any carotid stenosis were enrolled. All subjects had at least a major cardiovascular risk factor (CRF). Plasma levels of C-reactive protein (CRP), IL-6, and sCD40L were measured. Subjects were reviewed every 12 months (median follow-up, 8 years). Results— ALCS patients had higher ( P <0.0001) CRP, IL-6, and sCD40L than controls. Fourteen patients experienced a CV event. Cox regression analysis showed that only high sCD…

MaleRiskmedicine.medical_specialtySoluble CD40LCD40 LigandAsymptomaticatherosclerosiPredictive Value of TestsInternal medicineHumansrisk factorsMedicineRisk factorStrokeProportional Hazards ModelsAdvanced and Specialized NursingbiologyInterleukin-6business.industryProportional hazards modelVascular diseaseC-reactive proteinMiddle Agedmedicine.diseaseSurgeryStrokecarotid stenosiStenosisC-Reactive ProteinSolubilityinflammationPredictive value of testsbiology.proteinCardiologycarotid stenosisFemaleNeurology (clinical)atherosclerosismedicine.symptomatherosclerosis; carotid stenosis; inflammation; risk factorsCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesStroke
researchProduct

Fetuin-A and CD40L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory vari…

2009

Abstract Introduction Accumulating evidence suggests that inflammation plays an important role in the acute phase of ischemic stroke. CD40 L is a well recognized atherosclerotic inflammatory marker, whereas recent evidence suggests a pro-inflammatory role of Fetuin-A. To analyze the role of an inflammatory marker such as CD40 L and of a candidate pro-inflammatory marker such as Fetuin-A in acute stroke we evaluated their serum levels in subjects with acute ischemic stroke and their possible association with other laboratory and clinical variables. Materials and methods We enrolled 107 consecutive patients with a diagnosis of acute ischemic stroke admitted to the Internal Medicine Department…

Malemedicine.medical_specialtyPathologyalpha-2-HS-GlycoproteinCD40 LigandGastroenterologyBrain IschemiaCentral nervous system diseaseBrain ischemiaInternal medicineDiabetes mellitusWhite blood cellmedicineHumansStrokeAgedAged 80 and overbusiness.industryCerebral infarctionVascular diseaseBlood ProteinsMiddle Agedmedicine.diseaseStrokemedicine.anatomical_structureAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessFetuin-A CD40L strokealpha-2-HS-glycoprotein
researchProduct

MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

2022

Abstract Chronic lymphocytic leukemia (CLL) cells express the interleukin-23 receptor (IL-23R) chain, but the expression of the complementary IL-12Rβ1 chain requires cell stimulation via surface CD40 molecules (and not via the B-cell receptor [BCR]). This stimulation induces the expression of a heterodimeric functional IL-23R complex and the secretion of IL-23, initiating an autocrine loop that drives leukemic cell expansion. Based on the observation in 224 untreated Binet stage A patients that the cases with the lowest miR-146b-5p concentrations had the shortest time to first treatment (TTFT), we hypothesized that miR-146b-5p could negatively regulate IL-12Rβ1 side chain expression and clo…

MiceMicroRNAsCD40 LigandAnimalsReceptors Antigen B-CellChronic lymphocytic leukemia interleukin-23 receptor (IL-23R) MiR-146bSettore MED/05 - Patologia ClinicaRNA MessengerHematologySettore MED/08 - Anatomia PatologicaInterleukin-23Leukemia Lymphocytic Chronic B-CellBlood Advances
researchProduct

New pathways of increased cardiovascular risk in depression: a pilot study on the association of high-sensitivity C-reactive protein with pro-atheros…

2013

Abstract Background An elevation of inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) can be found in patients with depressive disorders. Inflammatory processes are known to influence atherosclerosis and might also mediate the link between depression and diabetes. The present study aimed at comparing hs-CRP and its relationship with atherogenic platelet markers in patients with type 2 diabetes (TD2) and/or newly diagnosed major depression (MD). Methods Hs-CRP concentrations in 24 patients with TD2, 21 patients with MD (diagnosed according to ICD-10 and DSM-IV), 19 patients with TD2 and comorbid MD, and 25 healthy controls were compared using analysis of variance. The…

OncologyAdultBlood PlateletsMalemedicine.medical_specialtyCD40 LigandMedizinPilot ProjectsType 2 diabetesDiseaseComorbidityRisk FactorsInternal medicineDiabetes mellitusmedicineHumansPlateletDepression (differential diagnoses)Depressive Disorder MajorCD40biologybusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseAtherosclerosisPsychiatry and Mental healthClinical PsychologyEndocrinologyC-Reactive ProteinDiabetes Mellitus Type 2Cardiovascular DiseasesCase-Control Studiesbiology.proteinFemaleAnalysis of variancebusinessBiomarkersJournal of affective disorders
researchProduct

Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?

2008

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyPostmenopausal womenbusiness.industryObstetricsCD40 LigandObstetrics and GynecologyMiddle AgedReproductive MedicineRaloxifene HydrochloridemedicineHumansRaloxifeneFemalebusinessOsteoporosis Postmenopausalmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand.

2008

AbstractPeripheral blood monocytes are plastic cells that migrate to tissues and differentiate into various cell types, including macrophages, dendritic cells, and osteoclasts. We have described the migration of cellular inhibitor of apoptosis protein 1 (cIAP1), a member of the IAP family of proteins, from the nucleus to the Golgi apparatus in monocytes undergoing differentiation into macrophages. Here we show that, once in the cytoplasm, cIAP1 is involved in the degradation of the adaptor protein tumor necrosis factor receptor–associated factor 2 (TRAF2) by the proteosomal machinery. Inhibition of cIAP1 prevents the decrease in TRAF2 expression that characterizes macrophage formation. We d…

TRAF2CytoplasmCellular differentiationImmunologyCD40 LigandDown-RegulationGene ExpressionGolgi ApparatusBiologyBiochemistryMonocytesProinflammatory cytokineInhibitor of Apoptosis ProteinsPhagocytes Granulocytes and MyelopoiesisPhagocytosisMacrophageHumansRNA Small InterferingCD40U937 cellMacrophagesSignal transducing adaptor proteinCell DifferentiationCell BiologyHematologyU937 CellsTNF Receptor-Associated Factor 2Molecular biologyCell biologybiology.proteinTumor necrosis factor alphaBlood
researchProduct

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

1997

Abstract The current study was carried out to elucidate the immunoregulatory changes induced by venom immunotherapy (VIT) in bee or wasp allergic subjects. All subjects included in this study had a history of severe systemic allergic reactions to stings of the respective insect as well as positive skin tests with the respective venom or venom-specific IgE in the sera. Parameters assessed in peripheral blood mononuclear cells (PBMC) before and after initiation of VIT (rush therapy reaching a maintenance dose of 100 micrograms venom injected subcutaneously within 1 week) were expression of CD3, CD4, CD8, CD45RA, CD45RO, interleukin (IL)-2 receptor (R) alpha, IL-4R, IL-12R, Fc epsilon RII, CD4…

Time Factorsmedicine.medical_treatmentImmunologyCD40 LigandDown-RegulationVenomWasp VenomsImmunoglobulin ELigandsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaTh2 CellsAntigens CDT-Lymphocyte SubsetsmedicineImmunology and AllergyHumansLymphocyte CountRNA MessengerCD40 AntigensCD40Membrane GlycoproteinsbiologyReceptors IgEInterleukinAntibodies MonoclonalInsect Bites and StingsReceptors InterleukinAllergensTh1 CellsInterleukin-10Receptors Interleukin-4Interleukin 10Bee VenomsCytokineDesensitization ImmunologicImmunologyAntigens Surfacebiology.proteinInterleukin-4AntibodyEuropean journal of immunology
researchProduct

Physiological activation of the IgH 3' enhancer in B lineage cells is not blocked by Pax-5.

1996

The mouse 3' enhancer contains a high-affinity binding site for the paired box protein Pax-5. Here, we demonstrate by genomic footprinting that the rat 3' enhancer contains a low-affinity binding site for Pax-5, which is occupied in activated splenic B cells. Thus, binding of Pax-5 to the IgH 3' enhancer appears to be evolutionarily conserved in rodents. Analysis of Pax-5 expression in primary B cells demonstrates that Pax-5 remains expressed after 4 days of lipopolysaccharide (LPS) induction, but is down-regulated in 5-day stimulated cells. Similarly, the expression of Pax-5 is down-regulated in vivo in activated large splenocytes, in contrast to small resting cells. Multimerization of the…

Transcriptional Activationcongenital hereditary and neonatal diseases and abnormalitiesanimal structuresImmunologyCD40 LigandDNA FootprintingHeterologousDown-RegulationReceptors Antigen B-CellEnhancer RNAsLymphocyte ActivationMiceGene expressionImmunology and AllergyAnimalsBinding siteEnhancerTranscription factorCells CulturedReporter geneB-LymphocytesCD40Membrane GlycoproteinsbiologyGenes ImmunoglobulinPAX5 Transcription FactorNuclear ProteinsMolecular biologyRatsUp-Regulationbody regionsDNA-Binding ProteinsRepressor ProteinsEnhancer Elements GeneticGene Expression Regulationembryonic structuresbiology.proteinTrans-Activatorssense organsTranscription FactorsEuropean journal of immunology
researchProduct

Therapeutic dosages of oral or transdermal estradiol did not modify sCD40L levels in postmenopausal women.

2008

The CD40/CD40L system is considered a crucial modulator of the inflammatory process underlying the progression and complication of atheroma plaques. The soluble fraction of CD40L (sCD40L) is a reliable indicator of the CD40/CD40L system. Our purpose was to investigate whether a therapeutic dose of estradiol, by either the oral or the transdermal route, was associated with changes in circulating levels of sCD40L. Forty-seven women completed a 4-week course of treatment with either oral estradiol valerate (2 mg/day, 20 women) or transdermal estradiol (50 microg/day, 27 women). Serum levels of sCD40L were measured by conventional enzyme-linked immunosorbent assay. Oral, but not transdermal est…

medicine.medical_specialtyDoseEndocrinology Diabetes and MetabolismCD40 LigandAdministration OralEnzyme-Linked Immunosorbent AssayPharmacologyAdministration CutaneousFollicle-stimulating hormoneEndocrinologyTherapeutic indexInternal medicinemedicineHumansCD40 AntigensTriglyceridesTransdermalmedicine.diagnostic_testEstradiolbusiness.industryTransdermal routeEstradiol valerateObstetrics and Gynecologymedicine.diseaseAtherosclerosisMenopausePostmenopauseEndocrinologyCholesterolFemaleFollicle Stimulating HormoneLipid profilebusinessmedicine.drugGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct